Journal article icon

Journal article

Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse

Abstract:
Purpose: A detailed analysis of hepatitis C virus (HCV) resistance-associated substitutions (RASs) is required to understand why people fail direct-acting antiviral therapies. This study was conducted to assess RASs in an analysis of 2 trials evaluating the second-generation NS3/4A protease inhibitor grazoprevir (GZR) in combination with peginterferon/ribavirin. Patients and methods: From a total of 113 participants with HCV genotype 1 infection, RASs ... Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's Version

Actions


Access Document


Files:
Publisher copy:
10.2147/IDR.S156581

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDM; Experimental Medicine
Role:
Author
Expand authors...
Merck & Co., Inc More from this funder
Publisher:
Dove Medical Press Publisher's website
Journal:
Infection and Drug Resistance Journal website
Volume:
2018
Issue:
11
Pages:
1119-1135
Publication date:
2018-08-08
Acceptance date:
2018-01-31
DOI:
EISSN:
1178-6973
ISSN:
1178-6973
Pubs id:
pubs:909461
URN:
uri:08a11e0c-1a3b-4bb6-8e4f-bee3ffbf1c30
UUID:
uuid:08a11e0c-1a3b-4bb6-8e4f-bee3ffbf1c30
Local pid:
pubs:909461

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP